Abstract
Abbreviations:
HIV (human immunodeficiency virus), SIV (simian immunodeficiency virus), AIDS (acquired immune deficiency syndrome), CCR5 (chemokine receptor 5), CXCR4 (chemokine receptor 4), ART (antiretroviral), PWH (people with HIV), CTL (cytolytic T lymphocytes), Th (T helper), PD-1 (programmed cell death protein 1), LAG-3 (lymphocyte-activation gene 3), TIGIT (T cell immunoreceptor with Ig and ITIM domains), GALT (gut-associated lymphoid tissue), LPS (lipopolysaccharide), HCV (hepatitis C virus), HBV (hepatitis B virus), CMV (cytomegalovirus), PRR (pattern recognition receptor), ASC (apoptosis-associated speck-like protein containing a caspase-recruitment domain), NLR (NOD-like receptors), NACHT (central nucleotide-binding oligomerization), ALR (AIM2-like receptors), AIM2 (absent from melanoma 2), PAMP (pathogen-associated molecular pattern), DAMP (danger-associated molecular patterns)Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Translational ResearchReferences
- Pneumocystis Pneumonia -- Los Angeles.MMWR. 1981; 30
- Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).Science. 1983; 220: 868-871https://doi.org/10.1126/science.6189183
- Human immunodeficiency virus (HIV).Transfus Med Hemother. 2016; 43: 203-222https://doi.org/10.1159/000445852
WHO. HIV data and statistics. 2022 Available at: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics. Accessed 08/22/2022.
World Health Organization. HIV/AIDS. 2022. https://www.who.int/news-room/fact-sheets/detail/hiv-aids. Accessed 08/22/2022.
- NLRP3 inflammasome signaling as a link between HIV-1 infection and atherosclerotic cardiovascular disease.Front Cardiovasc Med. 2020; 7: 95https://doi.org/10.3389/fcvm.2020.00095
- Probing the interface of HIV and inflammaging.Curr HIV/AIDS Rep. 2021; 18: 198-210https://doi.org/10.1007/s11904-021-00547-0
- Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.Lancet. 2008; 372: 293-299https://doi.org/10.1016/S0140-6736(08)61113-7
- Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.Prescrire Int. 2004; 13 (https://pubmed.ncbi.nlm.nih.gov/15532140/): 144-150
- HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty.J Gerontol A Biol Sci Med Sci. 2007; 62: 1279-1286https://doi.org/10.1093/gerona/62.11.1279
- What it means to age with HIV infection: years gained are not comorbidity free.JAMA Netw Open. 2020; 3e208023https://doi.org/10.1001/jamanetworkopen.2020.8023
- Aging, inflammation, and HIV infection.Top Antivir Med. 2012; 20: 101-105
- HIV infection, inflammation, immunosenescence, and aging.Annu Rev Med. 2011; 62: 141-155https://doi.org/10.1146/annurev-med-042909-093756
- Premature age-related comorbidities among HIV-infected persons compared with the general population.Clin Infect Dis. 2011; 53: 1120-1126https://doi.org/10.1093/cid/cir627
- HIV and aging: time for a new paradigm.Curr HIV/AIDS Rep. 2010; 7: 69-76https://doi.org/10.1007/s11904-010-0041-9
- Low-level HIV viremia is associated with microbial translocation and inflammation.J Acquir Immune Defic Syndr. 2013; 62: 129-134https://doi.org/10.1097/QAI.0b013e3182745ab0
- HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.BMJ. 2009; 338: a3172https://doi.org/10.1136/bmj.a3172
- Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells.J Infect Dis. 2011; 204: 1217-1226https://doi.org/10.1093/infdis/jir507
- CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART.AIDS. 2010; 24: 959-968https://doi.org/10.1097/QAD.0b013e328337b957
- Residual inflammation and viral reservoirs: alliance against an HIV cure.Curr Opin HIV AIDS. 2016; 11: 234-241https://doi.org/10.1097/COH.0000000000000230
- T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.J Infect Dis. 2003; 187: 1534-1543https://doi.org/10.1086/374786
- Early immune senescence in HIV disease.Curr HIV/AIDS Rep. 2010; 7: 4-10https://doi.org/10.1007/s11904-009-0038-4
- Immunologic biomarkers, morbidity, and mortality in treated HIV infection.J Infect Dis. 2016; 214: S44-S50https://doi.org/10.1093/infdis/jiw275
- Dissecting how CD4 T cells are lost during HIV infection.Cell Host Microbe. 2016; 19: 280-291https://doi.org/10.1016/j.chom.2016.02.012
- The Hitchhiker guide to CD4(+) T-cell depletion in lentiviral infection. A critical review of the dynamics of the CD4(+) T cells in SIV and HIV infection.Front Immunol. 2021; 12695674https://doi.org/10.3389/fimmu.2021.695674
- HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha.Blood. 2004; 104: 487-494https://doi.org/10.1182/blood-2003-12-4341
- CD8(+) T-cell response to HIV infection in the era of antiretroviral therapy.Front Immunol. 2019; 10: 1896https://doi.org/10.3389/fimmu.2019.01896
- The antibody response against HIV-1.Cold Spring Harb Perspect Med. 2012; 2a007039https://doi.org/10.1101/cshperspect.a007039
- Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000; 18: 665-708https://doi.org/10.1146/annurev.immunol.18.1.665
- Purinergic receptors: key mediators of HIV-1 infection and inflammation.Front Immunol. 2015; 6: 585https://doi.org/10.3389/fimmu.2015.00585
- HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation.Clin Infect Dis. 2012; 55: 126-136https://doi.org/10.1093/cid/cis406
- Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function.Clin Immunol. 2006; 120: 163-170https://doi.org/10.1016/j.clim.2006.04.570
- Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.Proc Natl Acad Sci U S A. 2009; 106: 9403-9408https://doi.org/10.1073/pnas.0903107106
- Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial.AIDS Res Ther. 2014; 11: 33https://doi.org/10.1186/1742-6405-11-33
- Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.AIDS. 2010; 24: 2451-2460https://doi.org/10.1097/QAD.0b013e32833ef7bb
- The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects.J Immunol. 2015; 194: 3873-3882https://doi.org/10.4049/jimmunol.1402176
- CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART.PLoS Pathog. 2016; 12e1005761https://doi.org/10.1371/journal.ppat.1005761
- The paradox of the immune response in HIV infection: when inflammation becomes harmful.Clin Chim Acta. 2013; 416: 96-99https://doi.org/10.1016/j.cca.2012.11.025
- Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue.Cell. 2010; 143 (In English): 789-801https://doi.org/10.1016/j.cell.2010.11.001
- Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection.Nature. 2014; 505 (In English): 509-514https://doi.org/10.1038/nature12940
- Cell-to-cell transmission of HIV-1 is required to trigger pyroptotic death of lymphoid-tissue-derived CD4 T cells.Cell Rep. 2015; 12 (In English): 1555-1563https://doi.org/10.1016/j.celrep.2015.08.011
- IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV.Science. 2014; 343 (In English): 428-432https://doi.org/10.1126/science.1243640
- Blood-derived CD4 T cells naturally resist pyroptosis during abortive HIV-1 infection.Cell Host Microbe. 2015; 18 (In English): 463-470https://doi.org/10.1016/j.chom.2015.09.010
- Gut microbiome homeostasis and the CD4 T- follicular helper cell IgA axis in human immunodeficiency virus infection.Front Immunol. 2021; 12657679https://doi.org/10.3389/fimmu.2021.657679
- Microbial translocation is a cause of systemic immune activation in chronic HIV infection.Nat Med. 2006; 12: 1365-1371https://doi.org/10.1038/nm1511
- Immune activation and HIV persistence: implications for curative approaches to HIV infection.Immunol Rev. 2013; 254: 326-342https://doi.org/10.1111/imr.12065
- Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.J Infect Dis. 2010; 201: 1788-1795https://doi.org/10.1086/652749
- Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection.Clin Infect Dis. 2017; 64: 124-131https://doi.org/10.1093/cid/ciw683
- Circulating LPS and (1–>3)-beta-D-Glucan: a Folie a Deux contributing to HIV-associated immune activation.Front Immunol. 2019; 10: 465https://doi.org/10.3389/fimmu.2019.00465
- Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction.Gut. 2020; 69: 191-193https://doi.org/10.1136/gutjnl-2018-317726
- HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS.Curr HIV Res. 2011; 9: 148-153https://doi.org/10.2174/157016211795945296
- Fecal microbiota composition drives immune activation in HIV-infected individuals.EBioMedicine. 2018; 30: 192-202https://doi.org/10.1016/j.ebiom.2018.03.024
- The mucosal barrier and immune activation in HIV pathogenesis.Curr Opin HIV AIDS. 2008; 3: 356-361https://doi.org/10.1097/COH.0b013e3282f9ae9c
- Microbial translocation and inflammation occur in hyperacute immunodeficiency virus infection and compromise host control of virus replication.PLoS Pathog. 2016; 12e1006048https://doi.org/10.1371/journal.ppat.1006048
- Purinergic receptors: elucidating the role of these immune mediators in HIV-1 fusion.Viruses. 2020; 12: 290https://doi.org/10.3390/v12030290
- P2X1 selective antagonists block HIV-1 infection through inhibition of envelope conformation-dependent fusion.J Virol. 2020; 94: e01622-19https://doi.org/10.1128/JVI.01622-19
- P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.J Virol. 2014; 88: 11504-11515https://doi.org/10.1128/JVI.01158-14
- P2RX7 at the host-pathogen interface of infectious diseases.Microbiol Mol Biol Rev. 2021; 85: e00055-20–20https://doi.org/10.1128/MMBR.00055-20
- Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.J Infect Dis. 2014; 210: 1228-1238https://doi.org/10.1093/infdis/jiu238
- CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.J Exp Med. 2004; 200: 749-759https://doi.org/10.1084/jem.20040874
- HIV disease: fallout from a mucosal catastrophe?.Nat Immunol. 2006; 7: 235-239https://doi.org/10.1038/ni1316
- Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract.J Exp Med. 2004; 200: 761-770https://doi.org/10.1084/jem.20041196
- Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction.PLoS Pathog. 2017; 13e1006202https://doi.org/10.1371/journal.ppat.1006202
- Immune activation response in chronic HIV-infected patients: influence of hepatitis C virus coinfection.PLoS One. 2015; 10e0119568https://doi.org/10.1371/journal.pone.0119568
- Role of inflammasomes in HIV-1 and drug abuse mediated neuroinflammaging.Cells. 2020; 9: 1857https://doi.org/10.3390/cells9081857
- HIV-1 and drug abuse comorbidity: lessons learned from the animal models of NeuroHIV.Neurosci Lett. 2021; 754135863https://doi.org/10.1016/j.neulet.2021.135863
- HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use.AIDS Care. 2009; 21: 655-663https://doi.org/10.1080/09540120802459762
- Imaging studies of the HIV-infected brain.Handb Clin Neurol. 2018; 152: 229-264https://doi.org/10.1016/B978-0-444-63849-6.00018-9
- Effect of cocaine on HIV infection and inflammasome gene expression profile in HIV infected macrophages.Sci Rep. 2016; 6: 27864https://doi.org/10.1038/srep27864
- Inflammasome in drug abuse.Int J Physiol Pathophysiol Pharmacol. 2017; 9: 165-177
- HIV-1 tat primes and activates microglial NLRP3 inflammasome-mediated neuroinflammation.J Neurosci. 2017; 37: 3599-3609https://doi.org/10.1523/JNEUROSCI.3045-16.2017
- HIV-1 viral protein R activates NLRP3 inflammasome in microglia: implications for HIV-1 associated neuroinflammation.J Neuroimmune Pharmacol. 2017; 12: 233-248https://doi.org/10.1007/s11481-016-9708-3
- Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS.Retrovirology. 2014; 11: 35https://doi.org/10.1186/1742-4690-11-35
- Serious non-AIDS events: therapeutic targets of immune activation and chronic inflammation in HIV infection.Drugs. 2016; 76: 533-549https://doi.org/10.1007/s40265-016-0546-7
- Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial.J Acquir Immune Defic Syndr. 2015; 68: 256-263https://doi.org/10.1097/QAI.0000000000000468
- Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients.HIV Med. 2013; 14: 530-539https://doi.org/10.1111/hiv.12046
- The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.Mol Cell. 2002; 10: 417-426https://doi.org/10.1016/s1097-2765(02)00599-3
- Inflammasomes: mechanism of action, role in disease, and therapeutics.Nat Med. 2015; 21: 677-687https://doi.org/10.1038/nm.3893
- Inflammasome complexes: emerging mechanisms and effector functions.Cell. 2016; 165: 792-800https://doi.org/10.1016/j.cell.2016.03.046
- Inflammasomes.Cold Spring Harb Perspect Biol. 2014; 6a016287https://doi.org/10.1101/cshperspect.a016287
- Function of Nod-like receptors in microbial recognition and host defense.Immunol Rev. 2009; 227: 106-128https://doi.org/10.1111/j.1600-065X.2008.00734.x
- Inflammasome activation and regulation: toward a better understanding of complex mechanisms.Cell Discov. 2020; 6: 36https://doi.org/10.1038/s41421-020-0167-x
- The inflammasomes.Cell. 2010; 140: 821-832https://doi.org/10.1016/j.cell.2010.01.040
- Recent insights on inflammasomes, gasdermin pores, and pyroptosis.Cold Spring Harb Perspect Biol. 2020; 12: a036392https://doi.org/10.1101/cshperspect.a036392
- The NLR gene family: a standard nomenclature.Immunity. 2008; 28: 285-287https://doi.org/10.1016/j.immuni.2008.02.005
- Inflammasomes: mechanism of assembly, regulation and signalling.Nat Rev Immunol. 2016; 16 (In English): 407-420https://doi.org/10.1038/nri.2016.58
- Caspase-4 mediates non-canonical activation of the NLRP3 inflammasome in human myeloid cells.Eur J Immunol. 2015; 45: 2911-2917https://doi.org/10.1002/eji.201545523
- ATP-binding and hydrolysis in inflammasome activation.Molecules. 2020; 25 (In English)https://doi.org/10.3390/molecules25194572
- The role of inflammasome activation in early HIV infection.J Immunol Res. 2021; 2021 (In English)1487287https://doi.org/10.1155/2021/1487287
- The interplay between viruses and host DNA sensors.Viruses. 2022; 14 (In English)https://doi.org/10.3390/v14040666
- Toll-like receptor (TLR) signaling enables cyclic GMP-AMP synthase (cGAS) sensing of HIV-1 Infection in macrophages.mBio. 2021; 12 (In English)e0281721https://doi.org/10.1128/mBio.02817-21
- Sensor sensibility-HIV-1 and the innate immune response.Cells. 2020; 9 (In English): 254https://doi.org/10.3390/cells9010254
- An update on cell intrinsic negative regulators of the NLRP3 inflammasome.J Leukoc Biol. 2018; 103 (In English): 1165-1177https://doi.org/10.1002/JLB.3MIR0917-350R
- Self-DNA sensing fuels HIV-1-associated inflammation.Trends Mol Med. 2019; 25 (In English): 941-954https://doi.org/10.1016/j.molmed.2019.06.004
- Nucleic acid sensing in mammals and plants: facts and caveats.Int Rev Cell Mol Biol. 2019; 345 (In English): 225-285https://doi.org/10.1016/bs.ircmb.2018.10.003
- The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis.Nat Immunol. 2009; 10: 241-247https://doi.org/10.1038/ni.1703
- The NLRP3 inflammasome: an overview of mechanisms of activation and regulation.Int J Mol Sci. 2019; 20: 3328https://doi.org/10.3390/ijms20133328
- NLRP3 inflammasome in neurological diseases, from functions to therapies.Front Cell Neurosci. 2017; 11: 63https://doi.org/10.3389/fncel.2017.00063
- The intersection of cell death and inflammasome activation.Cell Mol Life Sci. 2016; 73 (In English): 2349-2367https://doi.org/10.1007/s00018-016-2205-2
- Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death.Nature. 2015; 526 (In English): 660-665https://doi.org/10.1038/nature15514
- Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling.Nature. 2015; 526 (In English): 666-671https://doi.org/10.1038/nature15541
- HIV in the brain: identifying viral reservoirs and addressing the challenges of an HIV cure.Vaccines (Basel). 2021; 9: 867https://doi.org/10.3390/vaccines9080867
- Inflammasomes in the CNS.Nat Rev Neurosci. 2014; 15: 84-97https://doi.org/10.1038/nrn3638
- The NLRP3 inflammasome is upregulated in HIV-infected antiretroviral therapy-treated individuals with defective immune recovery.Front Immunol. 2018; 9: 214https://doi.org/10.3389/fimmu.2018.00214
- HIV-1 induces the first signal to activate the NLRP3 inflammasome in monocyte-derived macrophages.Intervirology. 2014; 57: 36-42https://doi.org/10.1159/000353902
- Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors.Cell Death Dis. 2019; 10: 128https://doi.org/10.1038/s41419-019-1413-8
- Role of inflammasomes in HIV-1 infection and treatment.Trends Mol Med. 2022; 28 (In English): 421-434https://doi.org/10.1016/j.molmed.2022.02.010
- HIV-1 Gag and Vpr impair the inflammasome activation and contribute to the establishment of chronic infection in human primary macrophages.Mol Immunol. 2022; 148 (In English): 68-80https://doi.org/10.1016/j.molimm.2022.04.018
- Ligand-gated purinergic receptors regulate HIV-1 tat and morphine related neurotoxicity in primary mouse striatal neuron-glia co-cultures.J Neuroimmun Pharmacol. 2014; 9: 233-244https://doi.org/10.1007/s11481-013-9507-z
- Adenosine triphosphate released from HIV-infected macrophages regulates glutamatergic tone and dendritic spine density on neurons.J Neuroimmun Pharmacol. 2013; 8: 998-1009https://doi.org/10.1007/s11481-013-9471-7
- Purinergic receptors are required for HIV-1 infection of primary human macrophages.J Immunol. 2012; 188 (Research Support, N.I.H., Extramural) (In English)): 4488-4495https://doi.org/10.4049/jimmunol.1102482
- Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages.Proc Natl Acad Sci U S A. 2015; 112: E3265-E3273https://doi.org/10.1073/pnas.1500656112
- Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection.J Exp Med. 2011; 208: 1823-1834https://doi.org/10.1084/jem.20101805
- HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse.J Exp Med. 2004; 199 (In English): 283-293https://doi.org/10.1084/jem.20030648
- Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1.J Virol. 2007; 81 (Research Support, N.I.H., Extramural): 12596-12607
Research Support, U.S. Gov't, Non-P.H.S.) (In English). 2022. DOI: 10.1128/JVI.01088-07. Sequence of Human Immunodeficiency Virus Type 1 (HIV-1) Gag Localization and Oligomerization Monitored with Live Confocal Imaging of a Replication-Competent, Fluorescently Tagged HIV-1 https://journals.asm.org/doi/10.1128/JVI.01088-07?cookieSet=1
- High-throughput HIV-cell fusion assay for discovery of virus entry inhibitors.Assay Drug Dev Technol. 2015; 13: 155-166https://doi.org/10.1089/adt.2015.639
- P2X1 receptor antagonists inhibit HIV-1 fusion by blocking virus-coreceptor interactions.J Virol. 2015; 89: 9368-9382https://doi.org/10.1128/JVI.01178-15
- P2X antagonists inhibit HIV-1 productive infection and inflammatory cytokines interleukin-10 (IL-10) and IL-1β in a human tonsil explant model.J Virol. 2019; 93 (10e01186-18(In English))https://doi.org/10.1128/JVI.01186-18
- Pannexin1 hemichannels are critical for HIV infection of human primary CD4+ T lymphocytes.J Leukoc Biol. 2013; 94 (Research Support, N.I.H., Extramural) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747: 399-407
Research Support, Non-U.S. Gov't). 2022. DOI: 10.1189/jlb.0512249.
- Editorial: pannexin-1—the hidden gatekeeper for HIV-1.J Leukoc Biol. 2013; 94: 390-392https://doi.org/10.1189/jlb.0313148
- Cell-to-cell transmission of HIV-1 is required to trigger pyroptotic death of lymphoid-tissue-derived CD4 T cells.Cell Rep. 2015; 12 (In English): 1555-1563https://doi.org/10.1016/j.celrep.2015.08.011
- Blood-derived CD4 T cells naturally resist pyroptosis during abortive HIV-1 infection.Cell Host Microbe. 2015; 18 (In English): 463-470https://doi.org/10.1016/j.chom.2015.09.010
- Next-generation mRNA sequencing reveals pyroptosis-induced CD4+ T cell death in early simian immunodeficiency virus-infected lymphoid tissues.J Virol. 2016; 90 (In English): 1080-1087https://doi.org/10.1128/JVI.02297-15
- Polymorphism in IFI16 affects CD4(+) T-cell counts in HIV-1 infection.Int J Immunogenet. 2014; 41 (In English): 518-520https://doi.org/10.1111/iji.12157
- Innate DNA sensing is impaired in HIV patients and IFI16 expression correlates with chronic immune activation.Clin Exp Immunol. 2014; 177 (In English): 295-309https://doi.org/10.1111/cei.12317
- Restriction factors expression decreases in HIV-1 patients after cART.New Microbiol. 2021; 44 (In English): 95-103
- IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication.Proc Natl Acad Sci U S A. 2013; 110 (In English): E4571-E4580https://doi.org/10.1073/pnas.1311669110
- Cellular factors targeting HIV-1 transcription and Viral RNA transcripts.Viruses. 2020; 12 (In English)https://doi.org/10.3390/v12050495
- IFI16 knockdown in primary HIV-1 target cells.STAR Protoc. 2021; 2 (In English)100236https://doi.org/10.1016/j.xpro.2020.100236
- Nuclear PYHIN proteins target the host transcription factor Sp1 thereby restricting HIV-1 in human macrophages and CD4+ T cells.PLoS Pathog. 2020; 16 (In English)e1008752https://doi.org/10.1371/journal.ppat.1008752
- IFI16 targets the transcription factor Sp1 to suppress HIV-1 transcription and latency reactivation.Cell Host Microbe. 2019; 25 (e13. (In English)): 858-872https://doi.org/10.1016/j.chom.2019.05.002
- Susceptibility to Mycobacterium tuberculosis infection in HIV-positive patients is associated with CARD8 genetic variant.J Acquir Immune Defic Syndr. 2013; 63 (In English): 147-151https://doi.org/10.1097/QAI.0b013e31828f93bb
- Polymorphisms in inflammasome' genes and susceptibility to HIV-1 infection.J Acquir Immune Defic Syndr. 2012; 59 (In English): 121-125https://doi.org/10.1097/QAI.0b013e3182392ebe
- CARD8 is an inflammasome sensor for HIV-1 protease activity.Science. 2021; 371 (In English)https://doi.org/10.1126/science.abe1707
- Beyond inhibition: a novel strategy of targeting HIV-1 protease to eliminate viral reservoirs.Viruses. 2022; 14 (In English)https://doi.org/10.3390/v14061179
- HIV replication is associated to inflammasomes activation, IL-1β, IL-18 and caspase-1 expression in GALT and peripheral blood.PLoS One. 2018; 13 (In English)e0192845https://doi.org/10.1371/journal.pone.0192845
- Human NLRP1 is a sensor for double-stranded RNA.Science. 2021; 371 (In English)https://doi.org/10.1126/science.abd0811
- Landscape of T cells transcriptional and metabolic modules during HIV infection based on weighted gene co-expression network analysis.Front Genet. 2021; 12 (In English)756471https://doi.org/10.3389/fgene.2021.756471
- Flagellin/NLRC4 pathway rescues NLRP3-inflammasome defect in dendritic cells from HIV-infected patients: perspective for new adjuvant in immunocompromised individuals.Front Immunol. 2019; 10 (In English): 1291https://doi.org/10.3389/fimmu.2019.01291
- DNA-encoded flagellin activates toll-like receptor 5 (TLR5), Nod-like receptor family CARD domain-containing protein 4 (NRLC4), and acts as an epidermal, systemic, and mucosal-adjuvant.Vaccines (Basel). 2013; 1 (In English): 415-443https://doi.org/10.3390/vaccines1040415
- A common NLRC4 gene variant associates with inflammation and pulmonary function in human immunodeficiency virus and tuberculosis.Clin Infect Dis. 2020; 71 (In English): 924-932https://doi.org/10.1093/cid/ciz898
- Differential recognition of HIV-stimulated IL-1β and IL-18 secretion through NLR and NAIP signalling in monocyte-derived macrophages.PLoS Pathog. 2021; 17 (In English)e1009417https://doi.org/10.1371/journal.ppat.1009417
- AIM2 inflammasome is activated by pharmacological disruption of nuclear envelope integrity.Proc Natl Acad Sci U S A. 2016; 113 (In English): E4671-E4680https://doi.org/10.1073/pnas.1602419113
- Pharmacological inhibitors of the NLRP3 inflammasome.Front Immunol. 2019; 10: 2538https://doi.org/10.3389/fimmu.2019.02538
- NLRP3 inflammasome and its inhibitors: a review.Front Pharmacol. 2015; 6 (In English): 262https://doi.org/10.3389/fphar.2015.00262
- A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.Nat Med. 2015; 21: 248-255https://doi.org/10.1038/nm.3806
- NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses.J Immunol. 2010; 185: 974-981https://doi.org/10.4049/jimmunol.0904145
- Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders.J Exp Med. 2017; 214: 3219-3238https://doi.org/10.1084/jem.20171419
- 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome.J Biol Chem. 2014; 289 (In English): 1142-1150https://doi.org/10.1074/jbc.M113.515080
- OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.Proc Natl Acad Sci U S A. 2018; 115: E1530-E1539https://doi.org/10.1073/pnas.1716095115
- Tranilast directly targets NLRP3 to treat inflammasome-driven diseases.EMBO Mol Med. 2018; 10: e8689https://doi.org/10.15252/emmm.201708689
- Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity.Nat Commun. 2018; 9: 2550https://doi.org/10.1038/s41467-018-04947-6
- ATP-sensitive potassium channelopathies: focus on insulin secretion.J Clin Invest. 2005; 115: 2047-2058https://doi.org/10.1172/JCI25495
- Glyburide inhibits the cryopyrin/Nalp3 inflammasome.J Cell Biol. 2009; 187: 61-70https://doi.org/10.1083/jcb.200903124
- A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome.Biochem Pharmacol. 2013; 85 (In English): 1504-1512https://doi.org/10.1016/j.bcp.2013.03.008
- Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].Am J Cardiol. 2013; 111: 1394-1400https://doi.org/10.1016/j.amjcard.2013.01.287
- Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse.Eur J Heart Fail. 2010; 12: 319-322https://doi.org/10.1093/eurjhf/hfq017
- Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases.Basic Res Cardiol. 2017; 113: 5https://doi.org/10.1007/s00395-017-0663-9
- Antiinflammatory therapy with canakinumab for atherosclerotic disease.N Engl J Med. 2017; 377: 1119-1131https://doi.org/10.1056/NEJMoa1707914
- The CB2 receptor and its role as a regulator of inflammation.Cell Mol Life Sci. 2016; 73 (In English): 4449-4470https://doi.org/10.1007/s00018-016-2300-4
- Endocannabinoid system components: overview and tissue distribution.Adv Exp Med Biol. 2019; 1162 (In English): 1-12https://doi.org/10.1007/978-3-030-21737-2_1
- Selective activation of cannabinoid receptor 2 attenuates myocardial infarction via suppressing NLRP3 inflammasome.Inflammation. 2019; 42: 904-914https://doi.org/10.1007/s10753-018-0945-x
- Activation of cannabinoid receptor 2 ameliorates DSS-induced colitis through inhibiting NLRP3 inflammasome in macrophages.PLoS One. 2016; 11e0155076https://doi.org/10.1371/journal.pone.0155076
- Activation of cannabinoid receptor type 2 attenuates surgery-induced cognitive impairment in mice through anti-inflammatory activity.J Neuroinflammation. 2017; 14 (In English): 138https://doi.org/10.1186/s12974-017-0913-7
- Cannabidiol modulates the immunophenotype and inhibits the activation of the inflammasome in human gingival mesenchymal stem cells.Front Physiol. 2016; 7 (In English): 559https://doi.org/10.3389/fphys.2016.00559
- Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells.PLoS One. 2012; 7 (In English): e33961https://doi.org/10.1371/journal.pone.0033961
- Probable deceleration of progression of Simian AIDS affected by opiate dependency: studies with a rhesus macaque/SIVsmm9 model.J Acquir Immune Defic Syndr. 2009; 50 (In English): 241-249https://doi.org/10.1097/QAI.0b013e3181967354
- Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor.J Pharmacol Exp Ther. 2010; 333: 319-327https://doi.org/10.1124/jpet.109.163055
- Cannabinoids and inflammation: implications for people living with HIV.AIDS. 2019; 33: 2273-2288https://doi.org/10.1097/QAD.0000000000002345